PAR-25-101 - Cutting-Edge Basic Research Awards (CEBRA) (R21 Clinical Trial Optional) is used for the submission of applications to the following Notices of Special Interest (NOSIs)
On This Page: 8
Active NOSIs
Title | Notice Number | Organization | Release Date |
Expiration Date |
Activity Code(s) |
---|---|---|---|---|---|
Notice of Special Interest (NOSI): Myelin plasticity in sculping addiction neurocircuitry | NOT-DA-25-028 | NIDA | Feb 26, 2024 | Jan 8, 2027 | F30, R03, F31, R01, K99/R00, R21, K01, F32 |
Notice of Special Interest (NOSI): Development and Application of Novel Chemical Approaches to Discover Therapeutic Targets for Substance Use Disorders | NOT-DA-25-027 | NIDA | Nov 28, 2023 | May 8, 2027 | K01, R21, F31, F30, R03, F32, R01, K99/R00 |
Notice of Special Interest (NOSI): Assembling the Addiction Organelle Interactome | NOT-DA-24-007 | NIDA | Apr 11, 2023 | Sep 8, 2026 | R21, K01, R36, R03, R01 |
Notice of Special Interest (NOSI): Leveraging glial cells to treat addiction | NOT-DA-24-006 | NIDA | Apr 3, 2023 | Sep 8, 2026 | R21, K01, R36, R01, R03 |
Notice of Special Interest (NOSI): Chemoproteomic Approaches for Discovery of Targets and Therapeutics to Treat Substance Use Disorders | NOT-DA-24-005 | NIDA | Nov 7, 2022 | Jan 8, 2026 | R03, F32, R21, F31, R01, K99/R00, F30, K01 |
Notice of Special Interest (NOSI) Targeting Epigenetic Regulators for Treating Addiction and Substance Use Disorders | NOT-DA-24-004 | NIDA | Nov 3, 2022 | Jan 8, 2026 | R03, R01, K99/R00, R21, F31, F30, F32, K01 |
Notices of Special Interest (NOSI): High Priority Areas in Integrative Neuroscience Branch in the Division of Neuroscience and Behavior | NOT-DA-22-058 | NIDA | Jun 2, 2022 | Jan 8, 2026 | R21, R03, R36, K01, K99/R00, R01 |
Notice of Special Interest (NOSI): Research in the Chemistry and Pharmacology of Addictive Drugs | NOT-DA-23-002 | NIDA | Nov 30, 2021 | Jan 8, 2025 | R03, R21, R01, K99/R00, R36, K01 |
Expired NOSIs
Title | Notice Number | Organization | Release Date |
Expiration Date |
Activity Code(s) |
---|